Breakthrough Infections in MPN-COVID Vaccinated Patients

Flacco M, Soldato G, Acuti Martellucci C, Di Martino G, Carota R, Caponetti A . Risk of SARS-CoV-2 Reinfection 18 Months After Primary Infection: Population-Level Observational Study. Front Public Health. 2022; 10:884121. PMC: 9108359. DOI: 10.3389/fpubh.2022.884121. View

Cattaneo D, Bucelli C, Cavallaro F, Consonni D, Iurlo A . Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience. Blood Cancer J. 2021; 11(11):185. PMC: 8616716. DOI: 10.1038/s41408-021-00579-0. View

Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Carioli G . Second versus first wave of COVID-19 in patients with MPN. Leukemia. 2022; 36(3):897-900. PMC: 8776551. DOI: 10.1038/s41375-022-01507-2. View

Ali E, Khamees I, Alshurafa A, Qasim H, Abu-Tineh M, Ahmed K . Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Patients with Philadelphia-Negative Myeloproliferative Neoplasm: A Single Center Experience. Oncology. 2022; 100(8):460-466. DOI: 10.1159/000525750. View

Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P . Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia. J Hematol Oncol. 2021; 14(1):119. PMC: 8319901. DOI: 10.1186/s13045-021-01130-1. View

Barbui T, Carobbio A, Ghirardi A, Iurlo A, Sobas M, Elli E . Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19. Am J Hematol. 2022; 97(12):E470-E473. PMC: 9538387. DOI: 10.1002/ajh.26732. View

Barbui T, Vannucchi A, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A . High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021; 35(2):485-493. PMC: 7789078. DOI: 10.1038/s41375-020-01107-y. View

Tada T, Zhou H, Dcosta B, Samanovic M, Mulligan M, Landau N . Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera. iScience. 2021; 24(11):103341. PMC: 8541826. DOI: 10.1016/j.isci.2021.103341. View

Leon T, Dorabawila V, Nelson L, Lutterloh E, Bauer U, Backenson B . COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021. MMWR Morb Mortal Wkly Rep. 2022; 71(4):125-131. PMC: 9351527. DOI: 10.15585/mmwr.mm7104e1. View

10.

Basic-Jukic N, Arnol M, Maksimovic B, Aleckovic-Halilovic M, Racki S, Barbic J . Clinical Characteristics and Outcomes of Kidney Transplant Recipients With SARS-CoV-2 Reinfections. Transplantation. 2022; 106(11):e501-e502. DOI: 10.1097/TP.0000000000004315. View

11.

Fiorino F, Sicuranza A, Ciabattini A, Santoni A, Pastore G, Simoncelli M . The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose. Biomedicines. 2021; 9(10). PMC: 8533286. DOI: 10.3390/biomedicines9101480. View

12.

Nachtigall I, Lenga P, Jozwiak K, Thurmann P, Meier-Hellmann A, Kuhlen R . Clinical course and factors associated with outcomes among 1904 patients hospitalized with COVID-19 in Germany: an observational study. Clin Microbiol Infect. 2020; 26(12):1663-1669. PMC: 7434317. DOI: 10.1016/j.cmi.2020.08.011. View

13.

Nordstrom P, Ballin M, Nordstrom A . Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet. 2022; 399(10327):814-823. PMC: 8816388. DOI: 10.1016/S0140-6736(22)00089-7. View